Definitive Healthcare (DH) Projected to Post Quarterly Earnings on Thursday

Definitive Healthcare (NASDAQ:DH) will likely be issuing its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $59.5660 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Definitive Healthcare Stock Up 0.6%

Shares of DH stock opened at $1.57 on Thursday. Definitive Healthcare has a 12 month low of $1.52 and a 12 month high of $5.39. The stock has a 50 day moving average of $2.31 and a 200-day moving average of $2.99. The firm has a market cap of $221.94 million, a PE ratio of -0.94 and a beta of 1.59. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 0.41.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Barclays decreased their price objective on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating on the stock in a report on Monday, December 8th. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a research note on Thursday, November 6th. Morgan Stanley reaffirmed an “underperform” rating and issued a $3.50 price target on shares of Definitive Healthcare in a research note on Thursday, December 18th. Wall Street Zen downgraded shares of Definitive Healthcare from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 28th. Finally, Canaccord Genuity Group cut their price objective on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.94.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its position in shares of Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after buying an additional 7,404,363 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Definitive Healthcare during the second quarter worth approximately $4,247,000. Inspire Investing LLC lifted its stake in Definitive Healthcare by 505.7% in the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock valued at $2,006,000 after buying an additional 583,562 shares during the period. Millennium Management LLC grew its position in shares of Definitive Healthcare by 230.9% during the 4th quarter. Millennium Management LLC now owns 332,087 shares of the company’s stock worth $953,000 after buying an additional 231,743 shares during the period. Finally, Jane Street Group LLC increased its stake in shares of Definitive Healthcare by 212.4% in the 2nd quarter. Jane Street Group LLC now owns 328,410 shares of the company’s stock valued at $1,281,000 after acquiring an additional 223,296 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.